Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption

(2014) Inbal Braunstein et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib

(2014) David A. Liebner et al.   MELANOMA RESEARCH

Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study

(2013) Reinhard Dummer et al.   EUROPEAN JOURNAL OF CANCER

Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology

(2013) Ozge Gumusay et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Severe Liver and Skin Toxicity After Radiation and Vemurafenib in Metastatic Melanoma

(2013) Christopher J. Anker et al.   JOURNAL OF CLINICAL ONCOLOGY

Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy

(2013) Imke Satzger et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity

(2013) Natalia Rompoti et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib and radiation therapy in melanoma brain metastases

(2013) Ashwatha Narayana et al.   JOURNAL OF NEURO-ONCOLOGY

Predictors of Survival, Neurologic Death, Local Failure, and Distant Failure After Gamma Knife Radiosurgery for Melanoma Brain Metastases

(2013) Matthew T. Neal et al.   World Neurosurgery

Successful Treatment With Vemurafenib in BRAF V600K–Positive Cerebral Melanoma Metastasis

(2013) Andrea Forschner et al.   JAMA Dermatology

Vemurafenib and Radiosensitization

(2013) Lise Boussemart et al.   JAMA Dermatology

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Haemorrhage due to proteolysis of FXIII and hyperfibrinolysis under vemurafenib treatment of metastatic melanoma

(2012) Ulrich Budde et al.   THROMBOSIS AND HAEMOSTASIS

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib

(2012) Elisa Castellani et al.   World Journal of Surgical Oncology

Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management

(2012) Pooya Jahanshahi et al.   Frontiers in Oncology

Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006

(2011) Ahmedin Jemal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032

(2011) Maria J. Sambade et al.   RADIOTHERAPY AND ONCOLOGY

Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival

(2010) Jan Zakrzewski et al.   CANCER

Outcome predictors of Gamma Knife surgery for melanoma brain metastases

(2010) Donald N. Liew et al.   JOURNAL OF NEUROSURGERY

MEK1 mutations confer resistance to MEK and B-RAF inhibition

(2009) C. M. Emery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Conformity of LINAC-Based Stereotactic Radiosurgery Using Dynamic Conformal Arcs and Micro-Multileaf Collimator

(2008) Lisa J. Hazard et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS